Content about Alemtuzumab

March 22, 2013

Genzyme drug shows improvement in MS patients

Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

August 27, 2012

Genzyme provides update on Lemtrada filing with FDA

Genzyme announced it has received a refuse-to-file letter from the Food and Drug Administration in response to the drug maker's supplemental biologics license application for the approval of Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis.

April 20, 2012

Genzyme to present MS drug trials

Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.

November 14, 2011

Genzyme announces phase-3 results of Lemtrada in patients with relapsing MS

A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.

March 7, 2011

Genzyme's board recommends shareholders OK Sanofi offer

The board of directors of Genzyme unanimously recommended that shareholders accept French drug maker Sanofi-Aventis’ $74-per-share buyout offer, Genzyme said Monday.

January 10, 2011

Sanofi, Genzyme get closer to deal

It appears that French drug maker Sanofi-Aventis’ efforts to acquire U.S. biotech company Genzyme are getting somewhere, according to company and media reports.

June 14, 2010

Genzyme's Campath gets fast-track designation from FDA

The Food and Drug Administration has agreed to speed up the review of a Genzyme...